Horizon Therapeutics (NASDAQ:HZNP) reported Q2 EPS of $1.07, $0.26 worse than the analyst estimate of $1.33. Revenue for the quarter came in at $876.4 million versus the consensus estimate of $936.11 million.
GUIDANCE:
Horizon Therapeutics sees FY2022 revenue of $3.53-3.6 million, versus the consensus of $3.96 million.